FIELD: immunobiotechnology, genetic engineering, medicine, pharmacy. SUBSTANCE: invention relates to novel monoclonal antibodies, methods for their preparing with using hybridoma technology and alpha.Vrho3-integrin or vitronectin as antigen, polypeptides representing light and heavy chain of antibodies and DNA encoding these polypeptides. These antibodies can be used as component of pharmaceutical composition for treatment of tumors, in part, melanoma and for diagnosis, localization and growth of tumor. Monoclonal antibody, in part 17E6 elicits the following properties: it interacts with alphaV-chain of human alphaV-integrins, blocks attachment of cells containing alphaV-integrins to the integrin substrate, affects the fixed interaction cell- matrix caused by alphaV-integrins, blocks tumor development and doesn't show cytotoxic activity. The use of novel monoclonal antibodies allows to block functions of the human integrin chain and to inhibit tumor development. EFFECT: improved preparing method, valuable med
